Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress [Yahoo! Finance]
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update